A best-evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was 'Is a fully heparin bonded cardiopulmonary bypass circuit superior to a standard cardiopulmonary bypass circuit?' Altogether more than 792 papers were found using the reported search, of which 13 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated ( Table 1) . The studies analysed show that perfusion with heparin-coated and heparin-polymer-coated bypass does not increase the risk of adverse effects but reduces blood loss, re-operation rates, ventilation time, length of intensive care unit (ICU) and hospital stay and is also associated with improved biocompatibility, as evidenced by platelet preservation, reduced leucocyte and complement activation, and proinflammatory cytokine production. The various coated circuits have comparable biocompatibility as evaluated by a range of inflammatory markers and clinical outcomes. Three studies documented a significant decrease in post-operative blood loss (P = 0.001-0.54) and a meta-analysis found that perfusion with a heparin-bonded circuit resulted in a reduction in blood transfusion requirements (20%), ventilation time (P < 0.01), length of time in the ICU (P < 0.01) and also hospital stay (P = 0.02). Two studies found reduced levels of polymorphonuclear elastase (P < 0.018-0.001) and two trials concluded that the use of heparin-coated circuits in combination with low-dose systemic heparin (activated clotting time >250) resulted in the greatest clinical benefit and improvement in inflammation. One study documented significant platelet preservation with the use of third-generation heparin-polymer-bonded circuits (P ≤ 0.05). We conclude that despite heparin-bonded and newer third-generation heparin-polymer-bonded cardiopulmonary bypass circuits having a greater cost per person, their improved clinical outcomes and biocompatibility in patients undergoing cardiac surgery make them a preferable option to standard non-heparin-bonded circuits.
INTRODUCTION
A best-evidence topic was constructed according to a structured protocol. This is fully described in the ICVTS [1] . 
THREE-PART QUESTION

CLINICAL SCENARIO
You are at a national conference hearing about the benefits of a heparin-bonded circuit (HBC) over a conventional cardiopulmonary bypass (CPB) circuit. An eminent speaker from the floor then stands up and contends that there have been no definitively proven benefits for HBC. You have a 67-year old patient, Jehovah's Witness, listed for elective aortic root and arch replacement. With a temptation to use an HBC, you decide to do a literature search. The biocompatibility of CPB, as assessed by complement activation, can be improved by coating the inner surfaces of these circuits with heparin
No complications occurred and all patients survived and were discharged from ICU on the first postoperative day Single-centre trial using a small sample, process of randomization and blinding not described HBCs have benefit over NHBCs in terms of incidence of blood transfusion, re-sternotomy rates, ventilation time, ICU-LOS and total hospital stay, but no significant difference in 24 h chest tube drainage The surface membrane-coated Avecor decrease intra-operative blood loss during surgery without affecting the overall blood transfusion requirement. Coated extracorporeal circuit offer no significant additional beneficial effects Single-centre trial using small sample size. Quantity of blood coming into contact with pericardium not measured 
Continued
SEARCH OUTCOME
The search returned 792 papers. From these, 13 papers provided the best evidence to answer the question. These are tabulated in Table 1 .
RESULTS
A number of studies have investigated the benefits of HBCs and all have found an associated improvement in biocompatibility.
McCarthy et al. [2] studied the effects of HBCs with full systemic heparinization in patients undergoing cardiac reoperations. No patient in the HBC coronary artery bypass grafting (CABG) subgroup required reoperation for bleeding (P = 0.058) and this group also had lower blood transfusion requirements (P = 0.035).
In addition, there were no adverse effects associated with the use of HBCs. Jansen et al. [3] observed an improvement in the clinical performance score of patients who underwent heparin-coated bypass and concluded that in combination with full systemic heparinization, HBCs improve biocompatibility, as assessed by complement activation.
Tayama et al. [4] demonstrated that heparin coating was associated with a partial improvement in biocompatibility with respect to leucocyte and complement activation and proinflammatory cytokine production. They found no significant differences in platelet activation, fibrinolysis, haemostasis time, 12 h post-operative blood loss, required amount of blood transfusion or the intubation time between groups and overall, the clinical benefit of HBCs seemed minimal.
Fosse et al. [5] executed a European multicentre trial comparing complement and granulocyte activation. They found that heparin coating reduced complement activation, particularly TCC formation, during bypass, but did not affect the release of specific neutrophil granule enzymes. There was no association between complement and granulocyte activation and clinical outcome, and no difference in myeloperoxidase or lactoferrin release between the groups.
Mangoush et al. [6] in 2007 performed a meta-analysis of 41 randomized controlled trials comparing HBCs and non-HBCs (NHBCs). They found that heparin coating improved clinical outcomes, as evidenced by a 40% reduction in re-sternotomy rates (P = 0.002) and a 20% reduction in patients requiring packed red cell transfusion. In addition, heparin coating reduced average ventilation time by 78 min, average ICU stay by 9.3 h (P < 0.001) and 
